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Clinical Outcomes of Molecular Tumor
Boards: A Systematic Review
Kara L. Larson, PhD1; Bin Huang, PhD1,2; Heidi L. Weiss, PhD1; Pam Hull, PhD1; Philip M. Westgate, PhD3; Rachel W. Miller, MD1,4;
Susanne M. Arnold, MD1,5; and Jill M. Kolesar, PharmD1,6

abstract

PURPOSE We conducted this systematic review to evaluate the clinical outcomes associated with molecular
tumor board (MTB) review in patients with cancer.
METHODS A systematic search of PubMed was performed to identify studies reporting clinical outcomes in
patients with cancer who were reviewed by an MTB. To be included, studies had to report clinical outcomes,
including clinical beneﬁt, response, progression-free survival, or overall survival. Two reviewers independently
selected studies and assessed quality with the Quality Assessment Tool for Before-After (Pre-Post) Studies with
No Control Group or the Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies
depending on the type of study being reviewed.
RESULTS Fourteen studies were included with a total of 3,328 patients with cancer. All studies included patients
without standard-of-care treatment options and usually with multiple prior lines of therapy. In studies reporting response
rates, patients receiving MTB-recommended therapy had overall response rates ranging from 0% to 67%. In the only
trial powered on clinical outcome and including a control group, the group receiving MTB-recommended therapy had
signiﬁcantly improved rate of progression-free survival compared with those receiving conventional therapy.
CONCLUSION Although data quality is limited by a lack of prospective randomized controlled trials, MTBs appear
to improve clinical outcomes for patients with cancer. Future research should concentrate on prospective trials
and standardization of approach and outcomes.
JCO Precis Oncol 5:1122-1132. © 2021 by American Society of Clinical Oncology
Creative Commons Attribution Non-Commercial No Derivatives 4.0 License
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Precision medicine, speciﬁcally testing tumor tissue
for mutations with next-generation sequencing (NGS)
and using these results to guide therapy, is a major
advance in the treatment of cancer and is considered
standard of care (SOC) for many cancer types, including lung cancer. Receiving a targeted therapy
yields substantial beneﬁt for patients, since randomized, controlled trials have demonstrated that they are
more effective, less toxic, and improve quality of life
compared with cytotoxic cancer treatments.1
Despite the availability of clinical and affordable NGS,
targeted therapies, and insurance coverage, the use of
precision medicine remains low often because of insufﬁcient support to guide clinicians in interpreting and
acting on NGS results.2-4 As a response, many medical
centers have instituted molecular tumor boards (MTBs)
as a means to educate, interpret, and facilitate the use
of precision medicine for oncology patients.5 Most
MTBs consist of a multidisciplinary team of medical
oncologists, surgeons, genetic counselors, pharmacists,

pathologists, radiologists, and basic scientists.6 This
broad range of expertise allows for accurate and up-todate conﬁrmation of diagnoses and identiﬁcation of
actionable mutations and associated drugs, along with
the ability to pair patients with open clinical trials. It can
additionally identify potential germline mutations that
would require further genetic testing and counseling for
patients and their family members.
Many institutions have published descriptions of their
MTBs outlining their aims, patient populations, and
types of actionable mutations; however, data supporting
the clinical utility of MTBs are lacking.7-9 Therefore, we
focus on reports that also include clinical outcomes
such as clinical beneﬁt (CB), response, and/or
progression-free survival (PFS). The purpose of this
systematic review is to evaluate the effect of MTBs on
clinical outcomes in patients with cancer.
METHODS
This review was performed following Preferred
Reporting Items for Systematic Reviews and MetaAnalyses guidelines for systematic reviews.10
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CONTEXT
Key Objective
What is the impact of a molecular tumor board on clinical outcomes?
Knowledge Generated
Molecular tumor boards reporting clinical outcomes had consistent structure and function. They are usually interdisciplinary,
function as a consult service, and appear to improve clinical outcomes, including response and progression-free survival;
however, studies are heterogeneous and data quality is limited.
Relevance
As the number of targetable mutations continues to increase and cancer care becomes even more complex, consultation with
an interdisciplinary molecular tumor board can help guide therapy selection for patients with cancer.

Search Strategy and Inclusion and Exclusion Criteria
A PubMed search was conducted on April 1, 2020, using the
following query: molecular tumor board [All Fields]. Further
publications were found through additional means including
a bibliography screen of all selected articles. Articles were
excluded if they were not in English, were reviews, described
MTBs for pediatric patients, or did not contain data about CB
or survival. All remaining articles were screened for relevancy, and any duplicates were removed.
Data Analysis
Data extraction was performed by two researchers (K.L.L.
and J.M.K.) for all publications examined. Any disagreement was discussed between the researchers, and a
conclusion was reached. Because of data diversity and
differences in study setup, a meta-analysis was not performed, and instead, data will be discussed using a description of the ﬁndings.
Calculations
The frequency of cases reviewed by each molecular tumor
board (MTB) was calculated using the following formula:
number of patients reviewed/ number of patients referred)
× 100.
The frequency of actionable mutations was calculated using
the following formula:
number of patients with an actionable mutation/
total number of patients reviewed by the MTB) × 100.
The frequency of patients who received MTB-directed targeted therapy was calculated using the following formula:
number of patients that received MTB-directed therapy/
number of patients with actionable mutations) × 100.
Outcomes were reported by the authors. For all crosssectional cohort studies, CB, if not explicitly provided,

was calculated by adding the number of patients who
achieved stable disease, partial response, or complete
response (CR). Overall response rate (ORR), if not explicitly
provided, was calculated by summing the number of patients who achieved partial response or CR. To calculate
rates regarding outcomes, the following formula was used:
number of patients with CB or ORR/
number of patients receiving MTB-directed therapy) × 100.
Finally, the outcomes if the trial employed and intention-totreat design were calculated using the following formula:
number of patients with CB or ORR, respectively/
total number of patients referred to the MTB) × 100.
Quality Assessment and Bias Determination
Quality assessment of the reviewed articles was performed
using either the Quality Assessment Tool for Before-After
(Pre-Post) Studies with No Control Group or the Quality
Assessment Tool for Observational Cohort and CrossSectional Studies depending on the type of study being
reviewed.11 Each of the above tools were created and
validated by the National Institutes of Health and were
developed to determine the concepts that are necessary for
critical review. Responses were yes, not reported (NR), or
not applicable. Two researchers (K.L.L. and J.M.K.) performed the assessments independently, and any disagreements were discussed and resolved.
Additionally, the same researchers (K.L.L. and J.M.K.)
reviewed the studies for risk using the tool To Assess the
Risk of Bias in Cohort Studies validated by the Cochrane
Institute.12 Each study was rated as deﬁnitely yes, probably
yes, probably no, and deﬁnitely no with the risk of bias
increasing from yes to no.
RESULTS
A total of 71 articles were retrieved through a PubMed
search. Titles and abstracts of 31 studies were reviewed for
inclusion criteria. Ten articles were selected for a full
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review, and four more were added after a screen of bibliographies and other additional resources. Fourteen total
articles were reviewed for this systematic analysis (Fig 1).
Study Characteristics
For inclusion in this systematic review, the studies had to
report CB, response rate, or survival among patients receiving MTB-recommended therapies. All studies were
observational, and the majority were retrospective. About
half of the studies screened fewer than 100 patients with a
range of 34-2,579 for all studies. The majority of studies
used large (more than 300 genes) commercial or in-house
panels, with two using in-house whole-exome sequencing
and one using a small (37 gene) panel. All studies took
place in the United States,13-22 France,23-25 or the
Netherlands26 with the majority being single institution
studies at academic medical centers. Eleven of the articles
outlined MTBs that had reviewed patient cases for more
than 1 year with only one reviewing for less than 1 year and
two not reporting duration of review.
The authors for all publications analyzed similar aims for
each of their tumor boards with one or all of the following
stated:
1. To investigate the rate of mutations and examine their
clinical utility,
2. To breakdown complex genomic reports and guide
treatment,
3. To increase access to up-to-date precision medicine
treatment options and clinical trials, and

4. To determine the efﬁcacy of a precision medicine
program.
The MTBs generally employed a consistent structure and
operations, composed of an interdisciplinary team of clinicians and scientists, and operated essentially as a consult
service, making recommendations to the treating physician
rather than managing patients. Inclusion of a genetics
counselor was common, but not universal. In most cases,
treating physicians ordered NGS testing and then referred
patients to the MTB for evaluation. In one study, the MTB
was responsible for approving NGS, and in another study,
all patients were enrolled in a prospective sequencing study
with only a fraction of cases reviewed by the MTB (Tables 1
and 2). All MTBs, with one exception, made recommendations on the basis of pathogenic or likely pathogenic
mutations, but one also included variants of unknown
signiﬁcance (Appendix Table A1).
Characteristics of the Patient Populations
Most of the MTBs described reviewed cases for multiple
solid tumors with the exceptions of Kaderbhai et al23 and
Koopman et al26 (non–small-cell lung cancer only), Parker
et al17 (breast cancer only), and Rodriguez-Rodriguez
et al20 (gynecologic malignancies only). The mean and
median patient age for all studies (with the exception of Tafe
et al,21 which did not report age for their patients) was in the
range of 50-68 years. The study population and/or eligibility
requirements for MTB review were similar across all
studies. The majority of patients had advanced-stage

Articles retrieved from
database
(N = 71)
Excluded
Non-English
Not relevant
(n = 39)
Articles selected for
title and abstract review
(n = 32)
Excluded
Reviews
Pediatric patients
No clinical benefit reported
(n = 22)

FIG 1. Study schema.

Articles selected for full
text review
(n = 10)
Additional records found
through other sources
(n = 4)
Articles included in the
final analysis
(n = 14)

1124 © 2021 by American Society of Clinical Oncology

Downloaded from ascopubs.org by UNIVERSITY KENTUCKY on October 12, 2021 from 128.163.008.074
Copyright © 2021 American Society of Clinical Oncology. All rights reserved.

JCO Precision Oncology

TABLE 1. Clinical Outcome of MTBs—Cross-Sectional Cohort Studies
Scope of MTB

Sequencing Method

Tumor Types

Age
(range),
Years

Prior Lines of
Therapy, Mean
(range)

Study Design
Prospective

Consult
Multidisciplinary
Treatment
recommendations

Commercial panels
In-house whole
exome

Solid and
hematologic

53 (1.5-86)

NR

Burkard et al14

Prospective

Consult
Multidisciplinary
Treatment
recommendations

Commercial panels
In-house panels
Single gene

Solid

57 (33-88)

2 (0-5)

Harada et al16

Retrospective

Consult
Multidisciplinary
Treatment
recommendations
Approved testing

Commercial panels
Panels at another
university

Solid

57 (range
NR)

NR

Kaderbhai et al23

Retrospective

Consult
Oncologist and
molecular biologists
Treatment
recommendations

In-house panel

NSCLC

61 (42-78)

2.3a (1-7)

Koopman et al26

Retrospective

Consult
Multidisciplinary
Treatment
recommendations

In-house panel

NSCLC

68 (36-89)

NR
68% with 0
32% with ≥ 1

RodriguezRodriguez
et al20

Prospective

Consult
Multidisciplinary
Treatment
recommendations

Commercial panels

Gynecologic

61 (22-80)

NR but only rare or
refractory
included

Schwaederle
et al18

Retrospective

Consult
Multidisciplinary
Treatment
recommendations

Commercial panels

Solid

56 (29-75)

Tafe et al21

Retrospective

Consult
Multidisciplinary
Treatment
recommendations

In-house panel

Solid

Trédan et al25

Prospective

Consult
Multidisciplinary
Treatment
recommendations

Small in-house panel
(ION torrent PGM)

Trivedi et al22

Retrospective

Consult
Multidisciplinary
Treatment
recommendations

Commercial panels

165

Frequency
Reviewed by
MTB

Outcomes If
Received MTB
Treatment

Outcomes If ITT

CB: 13 of 31
(42%)

38 of 38 (100%) 32 of 38 (84%)

9 of 32 (28%)

CB: 4 of 9 (44%) CB: 4 of 38
ORR: 2 of 9 (22%)
(11%)
ORR: 2 of 38
(5%)

132 of 192
(69%)

48 of 132 (36%)

15 of 48 (31%)

CB: 8 of 15 (53%) CB: 8 of 191
ORR: 3 of 15
(4%)
(20%)
ORR: 3 of 191
(2%)

48 of 50 (96%)

29 of 48 (60%)

9 of 29 (31%)

CB: 7 of 9 (78%)b CB: 7 of 50
ORR: 4 of 9 (44%)
(14%)
ORR: 4 of 50
(8%)

110 of 129
(85%)

76 of 110 (69%)

25 of 76 (33%)

CB: 17 of 21c
(81%)
ORR: 14 of 21
(67%)

CB: 17 of 129
(13%)
ORR: 14 of 129
(11%)

69

68 of 69 (99%)

64 of 68 (94%)

25 of 64 (39%)

CB: 16 of 25
(64%)
ORR: 10 of 25
(40%)

CB: 16 of 69
(23%)
ORR: 10 of 69
(14%)

3a (1-13)

34

34 of 34 (100%) 33 of 34 (97%)

12 of 33 (36%)

CB: 7 of 12 (58%) CB: 7 of 34
ORR: 3 of 12
(21%)
(25%)
ORR: 3 of 34
(9%)

NR

2a (1-7)

35

35 of 35 (100%) 18 of 35 (51%)

2 of 18 (11%)

CB: 2 of 2 (100%) CB: 2 of 35
ORR: 1 of 2 (50%)
(6%)
ORR: 1 of 35
(3%)

Solid and
hematologic

58 (44-63)

NR but only
advanced
disease

1,980 of 2,579
(77%)

163 of 1,032 (15%)

CB: 80 of 182d
(43%)
ORR: 23 of 182
(13%)

Solid

64 (37-82)

2.4 (1-6)

12 of 54 (22%)

CB: 9 of 12 (75%) CB: 9 of 54
ORR: 0 of 12 (0%)
(17%)
ORR: 0 of 54

191

50

129

2,579

54

92 of 141 (65%)

Frequency of Receiving
MTB Recommended
Therapy
31 of 92 (34%)

38

141 of 165
(85%)

Frequency of
Actionable
Mutations

1,032 of 1,980
(52%)

54 of 54 (100%) 54 (100%)

1125

Abbreviations: CB, clinical beneﬁt; ITT, intention to treat; MTB, molecular tumor board; NR, not reported; NSCLC, non–small-cell lung cancer; ORR, overall response rate.
a
Median.
b
Progression-free survival of 3 months considered stable disease.
c
Outcomes of four individuals on clinical trials NR.
d
Some pateints got more than one MTB-recommended therapy.
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Reference
Bryce et al13

Patients
Referred to
MTB
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TABLE 2. Clinical Outcome of MTBs—Before-After Studies
Scope of MTB

Sequencing Method

Tumor
Types

Ages
(range),
Years

Prior Lines of
Therapy, Mean
(range)

Patients
Referred to
MTB

Frequency
Reviewed by
MTB

Frequency of Receiving
MTB-Recommended
Therapy

Frequency of
Actionable
Mutations

Outcomes If
Received MTB
Treatment

Outcomes If
ITT

Reference

Study Design

Dalton
et al15

Commercial panels
Retrospective Consult
Multidisciplinary
Treatment
recommendations

Solid

59 (17-73)

2 (0-10)

155

155 of 155
(100%)

132 of 155 (85%) 28 of 132 (22%)

Median PFS (n)
MTB (22): 5
months, 95% CI,
2.9 to NR
Conv. (54): 3
months, 95% CI,
2.4 to 5
6-month PFS
probability (n)
MTB: 43%, 95%
CI, 26 to 71
Conv.: 20%, 95%
CI, 11 to 35

Parker
et al17

Commercial panels
Retrospective Consult
Multidisciplinary
Treatment
recommendations

Breast

59 (range
NR)

3a (1-13)

43

43 of 43
(100%)

40 of 43 (93%)

17 of 40 (43%)

CB: 7 of 43
CB: 7 of 17 (41%)
(16%)
ORR: 5 of 17 (29%)
PFS ratio ≥ 1.3 in 7 ORR: 5 of 43
(12%)
of 17 (41%)

Radovich
et al19

Prospective

Commercial panels
Consult
Multidisciplinary
Treatment
recommendations

Solid

55 (range
NR)

4a (2-6)

168

168 of 168
(100%)

NR

44 of NR

PFS ratio ≥ 1.3
MTB: 19 of 44
(43%)
Conv.: 3 of 57
(5%)
P , .0001
Median PFS
MTB: 86 days
Conv.: 49 days
HR = 0.55 (95%
CI, 0.38 to 0.84)

NA

Réda
et al24

Prospective

Consult
In-house WES but
Multidisciplinary
recommendations limited
Treatment
to panel
recommendations

Solid

65 (24-94)

2a (1-8)

506

386 of 506
(76%)

342 of 506 (68%) 79 of 342 (23%)
(included VUS)

PFS ratio ≥ 1.3
MTB: 12 of 48
(25%)
Conv.: 23 of 89
(26%)
NS
P = .8 (χ2 test)

NA

NA
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Abbreviations: CB, clinical beneﬁt; conv., conventional; HR, hazard ratio; ITT, intention to treat; MTB, molecular tumor board; NA, not applicable; NR, not reported; NS, not signiﬁcant; ORR, overall
response rate; PFS, progression-free survival; VUS, variants of unknown signiﬁcance; WES, whole-exome sequencing.
a
Median.
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TABLE 3. Quality Assessment of Before-After Studies
Dalton et al15

Parker et al17

Radovich et al19

Réda et al24

Clearly stated question or objective

No

No

Yes

No

Study eligibility clearly described

Yes

No

Yes

Yes

Participants’ representative

Yes

Yes

Yes

Yes

All eligible patients enrolled

Yes

NR

NR

NR

Sample size sufﬁcient

No

No

Yes

No

Quality Criteria

Intervention clearly described

Yes

Yes

Yes

Yes

Outcomes clearly deﬁned, valid, reliable, and assessed consistently

No

No

Yes

No

Outcome assessors blinded

No

No

No

No

Loss to follow-up ≤ 20%

Yes

Yes

NR

Yes

Statistical methods provide P for pre- to postchanges

No

Yes

Yes

No

Outcome measures taken multiple times before and after intervention

NA

NA

NA

NA

Statistical analysis for group to individual effect

NA

NA

NA

NA

Abbreviations: NA, not applicable; NR, not reported.

disease and had received several prior therapies with most
having exhausted all SOC options.
Quality Assessment
Study quality was analyzed using the quality assessment
tools provided by the National Institutes of Health.11 If the
main outcomes of a study included comparing survival on
an MTB-directed treatment with patients’ prior treatment,
the study was classiﬁed as before-after, and quality was
assessed with Quality Assessment Tool for Before-After
(Pre-Post) Studies with No Control Group (Table 3). All
other studies were classiﬁed as cross-sectional cohort
studies, and quality was assessed with Quality Assessment
Tool for Observational Cohort and Cross-Sectional Studies
(Table 4). Most groups reported similar eligibility requirements or described their patient populations, and almost all
patients were followed until progression on MTB therapy,
and therefore used an appropriate timeframe to measure
patient outcomes. Physician or patient choice, insurance,
geographic location of clinical trials, and waiting to exhaust
SOC options were the main reasons for not accepting MTB
recommendations.
Bias analysis was performed using the tool from the
Cochrane Institute.12 Nine of the 14 studies did not include
a matched control, neither a cohort of untreated patients
nor by comparing MTB-recommended therapies with the
patients’ prior therapy. This resulted in those studies receiving the lowest score in that category, but the overall
level of bias was low (Table 5).
Genetic Testing and Actionable Mutations
The types of sequencing varied among studies and within
studies. The majority of samples were sent to commercial
Clinical Laboratory Improvement Amendments laboratories
with the most common being FoundationOne. Some researchers used on-site clinical laboratories to perform all
DNA extraction and sequencing. The types of testing used

included whole-exome sequencing, gene panels, and
comparative genomic hybridization. Each study deﬁned an
actionable mutation differently with four18-20,22 of the 14
studies not deﬁning actionability at all. Those studies that
used on-site clinical laboratories also varied in their decision making in regard to somatic calls, using different
databases, and publications, to determine each patient’s
mutation proﬁle. We calculated actionability rates for each
study that provided sufﬁcient data as described in methods.
The frequency of actionable mutations ranged from 36% to
100%. Of note, the only MTB that considered tumor mutation burden an actionable mutation was the most recently
published.24 We diagrammed these actionability rates
along each study timeline in Appendix Figure A1 (for those
studies that included the timeframe of data collection). In
general, rates of actionability increased over time, likely
because of new targets and drug approvals. Exceptions
were Koopman et al,26 who only evaluated lung cancer,
where the most common targetable driver mutations have
been known for decades, and Parker et al17 and RodriguezRodriguez et al,20 who focused on breast and gynecological
malignancies, respectively, where new targetable have
been slow to be identiﬁed.
Clinical Outcomes
To assess clinical outcomes, studies were divided into
before-after or cross-sectional cohort studies. For the crosssectional cohort studies, the percentage of patients receiving MTB-recommended targeted therapies ranged
from 11% to 39%. Although reasons for not receiving an
MTB-directed therapy were not frequently reported, when
reported, the most common reasons were lack of actionable mutations, rapidly progressive disease, and when
clinical trials were recommended by the MTB, patients
were unwilling to travel or ineligible.14 The frequency of
patients achieving a CB from MTB-directed therapies
ranged from 42%14 to 100%,21 although one study21
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TABLE 4. Quality Assessment of Cross-Sectional Cohort Studies
Bryce
et al13

Burkard
et al14

Harada
et al16

Kaderbhai
et al23

Koopman
et al26

RodriguezRodriguez
et al20

Schwaederle
et al18

Tafe
et al21

Trédan
et al25

Trivedi
et al22

Clearly stated question
or objective

No

No

No

No

No

No

No

No

No

No

Deﬁned population

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Participation rate
of ≥ 50%

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Participant recruited
from the same
population

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Sample size justiﬁcation

No

No

No

No

No

No

No

No

No

No

Exposures measured
before the outcome

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

Quality Criteria

Sufﬁcient timeframe

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Different levels or
exposures examined

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

Exposure measures
clearly deﬁned

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Outcome measures
clearly deﬁned

No

No

No

No

No

No

No

No

No

No

Outcome assessors
blinded

No

No

No

No

No

No

No

No

No

No

Loss to followup ≤ 20%

Yes

Yes

Yes

NR

NR

Yes

NR

NR

NR

Yes

Compounding variables
measured

No

No

No

No

No

No

No

No

No

No

Abbreviations: NA, not applicable; NR, not reported.

reported clinical outcomes for only two patients. Kaderbhai
et al23 and Koopman et al26 reported excellent CB rates of
78% and 81%, respectively, in patients with non–small-cell
lung cancer. ORRs ranged from 0% to 67% reported by
Trivedi et al22 and Koopman et al,26 respectively, with none
of the patients in Trivedi’s study achieving a partial or CR.

approach, deﬁned as proportion of individuals who received a recommendation on the basis of their genomic
report. Overall, 79 received a recommended therapy;
however, there was no difference proportion of patients
achieving a PFS of ≥ 1.3 between genomically targeted and
standard therapy.

For the before-after studies, the percentage of patients
receiving MTB-recommended targeted therapies ranged
from 22% to 43%. There were two prospective trials reported, the ﬁrst by Radovich et al19 who prospectively
compared the PFS ratio and PFS for 168 patients referred
to their MTB. Of these, 67 were lost to follow-up or had
insufﬁcient follow-up duration and were excluded. Of the
remainder, 44 received a genomically targeted therapy and
57 received nontargeted therapy. Patients with an actionable mutation and receiving a targeted therapy had
improved PFS (mean 86 days) compared with those not
receiving genomic therapy (mean 49 days, hazard ratio:
0.55, 95% CI, 0.37 to 0.84). In addition, 43.2% of those
with a targeted therapy achieved a PFS ratio of ≥ 1.3,
compared with only 5.3% of those with nontargeted therapy, P , .0001. Réda et al24 evaluated 506 patients who
were referred for NGS and were able to perform sequencing
on 386. The primary end point was feasibility of the

DISCUSSION
Somatic genomic sequencing has added additional layers
of complexity to diagnosing and treating cancer. Molecular
tumor boards have been developed to assist with assessing
and acting on genomic reports.6,27 All the studies analyzed
for this review stated similar aims for their molecular tumor
boards, using them as an opportunity to break down the
complexity of genomic testing and reporting, increase
access to up-to-date treatments and clinical trials, and
better understand the clinical utility of precision medicine in
oncology.
Nine of the 14 studies analyzed for this review had CB and/
or response rate as the primary outcome. None of these
studies were randomized nor were they controlled for
non–MTB-directed outcomes, thus making it difﬁcult to
determine the effectiveness of molecular targeted therapies
and the recommendations of their MTBs. ORRs in these
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TABLE 5. Risk of Bias of All Studies
Bryce
et al13

Burkard
et al14

Dalton
et al15

Harada
et al16

Kaderbhai
et al23

Koopman
et al26

Parker
et al17

Radovich
et al19

Réda
et al24

RodriguezRodriguez
et al20

Schwaederle
et al18

Tafe
et al21

Trédan
et al25

Trivedi
et al22

Selection of
exposed and
nonexposed
cohorts drawn
from the same
population

1

1

1

1

1

1

1

1

1

1

1

1

1

1

Conﬁdent in the
assessment of
exposure

1

1

1

1

1

1

1

1

1

1

1

1

1

1

Conﬁdent that the
outcome was not
present at start of
study

1

1

1

1

1

1

1

1

1

1

1

1

1

1

Exposed and
unexposed
matched for all
variables

4

4

4

4

4

4

4

4

4

4

4

4

4

4

Conﬁdent in the
assessment of
the presence or
absence of
prognostic
factors

4

4

4

4

4

4

4

4

4

4

4

4

4

4

Conﬁdence in the
assessment of
outcome

3

3

3

3

3

3

3

2

3

3

3

3

3

3

Follow-up of
cohorts
adequate

2

2

2

2

2

2

2

2

2

2

2

2

2

2

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

Bias Criteria

Cointerventions
similar between
groups

NOTE. 1, deﬁnitely yes; 2, probably yes; 3, probably no; 4, deﬁnitely no.
Abbreviation: NA, not applicable.

studies ranged from 0% to 67%, which favorably compared
with previously published ORRs of 5% in unmatched phase I
trials28 and 6% for all phase I trials in a single institution.29
Trédan et al22 not only had the largest patient cohort but also
used the smallest gene panel for their NGS testing, resulting
in a relatively low rate of patients with an actionable mutation.
Koopman et al26 reported a high CB in patients receiving an
off-label drug, but the authors indicated stricter criteria for
off-target therapies than other studies, denoting that mutations in downstream pathways were not considered for offtarget therapies of an upstream protein.

difﬁcult; however, generally, positive beneﬁts were seen.
Outcomes reported in trials without a control arm did appear to be much better than in other salvage situations such
as phase I trial responses from the era before targeted
therapy.29,30 Among those trials with a control arm, while
not conclusive, MTBs provide CB and at least do no harm.
In addition, overall impressions from the authors of each
study were positive in regard to the utility of the MTBs at
their respective institutions and suggested that each MTB
helped to inform treatment decisions and increase access
to genetic counseling for patients.

The three studies that either used patients’ PFS ratio or
compared PFS between patient groups allowed for a more
direct analysis of the efﬁcacy of the MTB-directed therapies. Of these, one was positive,19 one trended toward
superiority,15 and one found no difference.24 Since PFS
typically decreases with every subsequent therapy, a minor
increase in PFS2 may be noteworthy in this population.30

Although clinical trials comparing targeted therapies with
standard therapies in those with a biomarker are almost
universally positive, the reported beneﬁt of NGS for the
selection of therapy has been mixed. Several NCI-MATCH
study arms demonstrate promising results. In arm H, patients with BRAFV600 mutations were treated with dabrafenib and trametinib. This arm met its primary end point,
with an ORR of 33%.31 The MOSCATO trial concluded that
NGS improved outcomes, but only among a small subset of
patients with targetable mutations.32 The SHIVA trial was a

Comparing outcomes across a wide variety of reports with
different primary outcomes, patient populations, and criteria for recommendations makes deﬁnitive conclusions
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randomized phase II trial that included patients with a
mutation in one of the three pathways, hormone receptors,
PI3K, or RAF, and matched them to one of the 11 different
targeted therapies. In this trial, there was no improvement
in survival after treatment with targeted therapies.33 The
SHIVA trial has been criticized for its design, for both
assigning therapies with unproven activity for the targets
and using an algorithm that only considered mutations in
the targeted arm, whereas physician discretion was allowed
in the control arm. The number of patients eligible for
targeted therapies increased between 2006 and 2018,
likely because of more targeted therapy approvals every
year, but that fewer than 7% actually beneﬁtted, whereas
only 16% were eligible.34
Advances in NGS technologies are also identifying additional patients with actionable mutations. High tumor
mutation burden, an indication for pembrolizumab in any
tumor type,31 loss of heterozygosity, an indication for poly
(ADP-ribose) polymerase inhibition for prostate cancer,32
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and certain RNA fusions, which confer sensitivity to speciﬁc
targeted therapies, are now routinely reported on many
NGS panels.33 In addition, there is an increasing awareness
of the ability of somatic mutation testing to identify potential
germline mutations.35 In addition to being targetable with
small molecules, these germline mutations are clinically
important to the patient’s family members and support the
need for inclusion of genetic counselors in the MTB team.
As the number of eligible patients continues to rise, it will
become increasingly important for clinicians to accurately
interpret complex genomic test results and to have increased access to therapies and clinical trials. Resources
such as interprofessional MTBs can help clinicians navigate the complex world of precision medicine and provide
these advanced treatments to their patients. Furthermore,
as larger cohorts of data become available and shared,
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APPENDIX

69%—Koopman et al
100%—Trivedi et al
67%—Réda et al
84%—Burkard et al
85%—Dalton et al
52%—Trédan et al
94%—Rodriguez et al
93%—Parker et al
65%—Bryce et al
60%—Kaderbhai et al

2012

2013

2014

2015

2016

2017

2018

2019

Year
FIG A1. Actionability rates by year.

TABLE A1. Deﬁnitions of Actionability as Provided by the Authors
Reference

Deﬁnition of Actionability

Bryce et al

13

An aberration with known functional signiﬁcance that could be
therapeutically targeted with an FDA-approved drug or clinical trial

Burkard et al14

Allowed for identiﬁcation of a molecular-targeted clinical trial or off-trial
treatment

Dalton et al15

Offered a target for a drug approved by the FDA, an FDA-approved drug
off-label, a clinical trial, or was a potential germline mutation for a
hereditary syndrome

Harada et al16

Variants classiﬁed as predictive or prognostic of any tumor types or have
been reported in cancer and had available clinical trials

Kaderbhai et al23

Associated with FDA-approved drugs, potentially targetable when
associated with a clinical trial or potential sensitivity to a drug

Koopman et al26

Tier 1 or 2 according to 2017 American College of Medical Genetics
guidelines or existence of effective targeted therapy options

Parker et al17

An FDA-approved drug or in clinical trials that targeted at low nanomolar
concentrations or was the primary target of an antibody

Radovich et al19

NR

Réda et al

24

Class I-III variants with some class IV according to European Society of
Medical Oncology Scale for Clinical Actionability of Molecular Tests
guidelines, included some VUS

Rodriguez-Rodriguez et al20
Schwaederle et al

18

NR

Tafe et al21

Associated with available (approved, off-label, or experimental) targeting
of the affected pathway

Trédan et al25
Trivedi et al

NR

NR

22

Linked as either a positive or negative biomarker for an approved therapy
or enrollment criteria for an open clinical trial

Abbreviations: FDA, US Food and Drug Administration; NR, not reported; VUS, variants of unknown signiﬁcance.
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